 |
 |
|
|
|
 |
|
|
Bavarian Nordic (CSE: BAVA) is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 260 people.
Bavarian Nordic’s patented technology, MVA-BN®, is as been demonstrated in clinicial studies, one of the world’s safest, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer.
Several MVA-BN®-based HIV, cancer and smallpox vaccines are in clinical Phase I and Phase II trials.
Bavarian Nordic has ongoing development contracts with the US government (awarded in June 2007*, September 2004** and February 2003) to develop IMVAMUNE® as a safe third-generation smallpox vaccine. Bavarian Nordic’s advanced clinical development programme has been further expedited by the US government with the FDA’s grant of “fast-track” status for IMVAMUNE®, the first-ever smallpox vaccine candidate to be given this designation.
Bavarian Nordic has supplied several governments with smallpox vaccines and with its increased production capacity, able to supply the growing demand, particularly for safe smallpox vaccines. With a global manufacturing capacity consisting of its new state-of-the-art production facility in Denmark with a minimum capacity of 40 million doses per year and an ongoing partnership with the German vaccine producer, Impfstoffwerk Dessau-Tornau (IDT), Bavarian Nordic has ensured supply of its current and future vaccines.
Bavarian Nordic’s partners include Pharmexa, Impfstoffwerk Dessau-Tornau (IDT) and Vaccine Solutions.
* The award of RFP-3 has been funded in whole with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C.
** The award of RFP-2 has been funded in full or in part with federal funds from the National Institutes of Allergy and Infectious Diseases, the National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200400072C, ADB Contract No. 1-AI-40072.
|
|
|
|
|
|
